| 0.765 0 (0%) | 11-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer. This innovative test is promoted to various medical specialists, including professionals in breast healthcare and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment experts like breast surgeons. Beyond BREVAGenplus, the company's portfolio includes other cancer risk assessment tests marketed under the 'GeneType' brand, notably 'GeneType for Colorectal Cancer' and 'GeneType for Breast Cancer'. Furthermore, Genetic Technologies is actively developing additional risk assessment tools for a diverse range of conditions, such as cardiovascular diseases, type 2 diabetes, prostate cancer, and melanoma. Its services extend to general genetic testing, encompassing applications in medical, animal, forensic, and plant diagnostics. Genetic Technologies maintains active research and collaboration agreements with several prestigious institutions, including the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, The Ohio State University, and Shivom. The company was established in 1987 and operates from its headquarters in Fitzroy, Australia.
Fri, 19 Jun 2026
Gene Therapy Market Size to Hit USD 63.52 Billion by 2035 - Precedence Research
Thu, 28 May 2026
Genetic engineering - DNA Modification, Cloning, Gene Splicing - Encyclopedia Britannica
Thu, 23 Oct 2025
New Gene-Editing Tech Holds Promise for Treating Complex Genetic Diseases - The University of Texas at Austin
Wed, 17 Sep 2025
What Are GTTs? These Technologies Can Impact How a Gene Functions - Novartis
Wed, 23 Jul 2025
Gene editing technology could be used to save species on the brink of extinction - The Conversation
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|